PMC:7228307 / 40532-40944 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"682","span":{"begin":155,"end":159},"obj":"Gene"},{"id":"683","span":{"begin":181,"end":185},"obj":"Gene"},{"id":"693","span":{"begin":259,"end":263},"obj":"Gene"},{"id":"694","span":{"begin":22,"end":26},"obj":"Gene"},{"id":"695","span":{"begin":207,"end":212},"obj":"Species"},{"id":"696","span":{"begin":114,"end":123},"obj":"Chemical"},{"id":"697","span":{"begin":137,"end":148},"obj":"Chemical"},{"id":"698","span":{"begin":165,"end":174},"obj":"Chemical"},{"id":"701","span":{"begin":69,"end":74},"obj":"Disease"}],"attributes":[{"id":"A682","pred":"tao:has_database_id","subj":"682","obj":"Gene:2064"},{"id":"A683","pred":"tao:has_database_id","subj":"683","obj":"Gene:1956"},{"id":"A693","pred":"tao:has_database_id","subj":"693","obj":"Gene:2213"},{"id":"A694","pred":"tao:has_database_id","subj":"694","obj":"Gene:2213"},{"id":"A695","pred":"tao:has_database_id","subj":"695","obj":"Tax:9606"},{"id":"A696","pred":"tao:has_database_id","subj":"696","obj":"MESH:D000069283"},{"id":"A697","pred":"tao:has_database_id","subj":"697","obj":"MESH:D000068878"},{"id":"A698","pred":"tao:has_database_id","subj":"698","obj":"MESH:D000068818"},{"id":"A701","pred":"tao:has_database_id","subj":"701","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T352","span":{"begin":218,"end":226},"obj":"Body_part"}],"attributes":[{"id":"A352","pred":"fma_id","subj":"T352","obj":"http://purl.org/sig/ont/fma/fma13478"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T64","span":{"begin":57,"end":61},"obj":"Disease"},{"id":"T65","span":{"begin":69,"end":74},"obj":"Disease"}],"attributes":[{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0008734"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T722","span":{"begin":22,"end":24},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T723","span":{"begin":205,"end":206},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T724","span":{"begin":207,"end":212},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T725","span":{"begin":243,"end":253},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T726","span":{"begin":259,"end":261},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T727","span":{"begin":299,"end":307},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T211","span":{"begin":27,"end":35},"obj":"Chemical"},{"id":"T212","span":{"begin":114,"end":123},"obj":"Chemical"}],"attributes":[{"id":"A211","pred":"chebi_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"},{"id":"A212","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_64357"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T206","span":{"begin":36,"end":45},"obj":"http://purl.obolibrary.org/obo/BFO_0000034"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"682","span":{"begin":155,"end":159},"obj":"Gene"},{"id":"683","span":{"begin":181,"end":185},"obj":"Gene"},{"id":"693","span":{"begin":259,"end":263},"obj":"Gene"},{"id":"694","span":{"begin":22,"end":26},"obj":"Gene"},{"id":"695","span":{"begin":207,"end":212},"obj":"Species"},{"id":"696","span":{"begin":114,"end":123},"obj":"Chemical"},{"id":"697","span":{"begin":137,"end":148},"obj":"Chemical"},{"id":"698","span":{"begin":165,"end":174},"obj":"Chemical"},{"id":"701","span":{"begin":69,"end":74},"obj":"Disease"}],"attributes":[{"id":"A701","pred":"pubann:denotes","subj":"701","obj":"MESH:D009369"},{"id":"A698","pred":"pubann:denotes","subj":"698","obj":"MESH:D000068818"},{"id":"A694","pred":"pubann:denotes","subj":"694","obj":"Gene:2213"},{"id":"A696","pred":"pubann:denotes","subj":"696","obj":"MESH:D000069283"},{"id":"A697","pred":"pubann:denotes","subj":"697","obj":"MESH:D000068878"},{"id":"A682","pred":"pubann:denotes","subj":"682","obj":"Gene:2064"},{"id":"A693","pred":"pubann:denotes","subj":"693","obj":"Gene:2213"},{"id":"A695","pred":"pubann:denotes","subj":"695","obj":"Tax:9606"},{"id":"A683","pred":"pubann:denotes","subj":"683","obj":"Gene:1956"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T42","span":{"begin":207,"end":212},"obj":"Species"}],"attributes":[{"id":"A42","pred":"ncbi_taxonomy_id","subj":"T42","obj":"NCBItxid:9606"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T229","span":{"begin":0,"end":412},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T386","span":{"begin":130,"end":134},"obj":"Protein"}],"attributes":[{"id":"A386","pred":"uniprot_id","subj":"T386","obj":"https://www.uniprot.org/uniprot/Q3C2E2"},{"id":"A387","pred":"uniprot_id","subj":"T386","obj":"https://www.uniprot.org/uniprot/Q13963"},{"id":"A388","pred":"uniprot_id","subj":"T386","obj":"https://www.uniprot.org/uniprot/P19437"},{"id":"A389","pred":"uniprot_id","subj":"T386","obj":"https://www.uniprot.org/uniprot/P11836"},{"id":"A390","pred":"uniprot_id","subj":"T386","obj":"https://www.uniprot.org/uniprot/P08984"},{"id":"A391","pred":"uniprot_id","subj":"T386","obj":"https://www.uniprot.org/uniprot/B4DT24"},{"id":"A392","pred":"uniprot_id","subj":"T386","obj":"https://www.uniprot.org/uniprot/A6NMS4"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T351","span":{"begin":218,"end":226},"obj":"Body_part"}],"attributes":[{"id":"A351","pred":"fma_id","subj":"T351","obj":"http://purl.org/sig/ont/fma/fma13478"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T103","span":{"begin":57,"end":61},"obj":"http://purl.obolibrary.org/obo/GO_0001788"},{"id":"T104","span":{"begin":181,"end":185},"obj":"http://purl.obolibrary.org/obo/GO_0005006"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T22","span":{"begin":69,"end":74},"obj":"Disease"}],"attributes":[{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T12","span":{"begin":69,"end":74},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T103","span":{"begin":57,"end":61},"obj":"http://purl.obolibrary.org/obo/GO_0001788"},{"id":"T104","span":{"begin":181,"end":185},"obj":"http://purl.obolibrary.org/obo/GO_0005006"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T103","span":{"begin":57,"end":61},"obj":"http://purl.obolibrary.org/obo/GO_0001788"},{"id":"T104","span":{"begin":181,"end":185},"obj":"http://purl.obolibrary.org/obo/GO_0005006"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-sentences","denotations":[{"id":"T229","span":{"begin":0,"end":412},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T12","span":{"begin":69,"end":74},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design."}